comparemela.com

Latest Breaking News On - B cell neoplasia unit - Page 1 : comparemela.com

Unlocking Long-Term Success: Insights From 5-Year Follow-Up of the CAPTIVATE Trial in CLL/SLL

Paolo Ghia, MD, PhD, discusses long-term efficacy data for fixed-duration ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia.

San diegoUnited statesPaolo ghiaDivision of experimental oncologyStrategic research programSan raffaele scientific instituteExperimental oncologyB cell neoplasia unitVita salute san

Zanubrutinib Improves PFS in Treatment-Naive CLL/SLL, Regardless of Complex Karyotypes

Paolo Ghia, MD, PhD, describes the various cohorts of the SEQUOIA study, expands on outcomes from a biomarker subgroup analysis with zanubrutinib vs bendamustine plus rituximab, and more.

San raffaele scientific instituteDivision of experimental oncologyStrategic research programB cell neoplasia unitVita salute sanExperimental oncologyPhase 3 sequoia trial nct03336333

Dr Ghia on a Biomarker Analysis of the SEQUOIA Trial in CLL/SLL

Paolo Ghia, MD, PhD, full professor, discusses a biomarker subgroup analysis of the phase 3 SEQUOIA trial investigating zanubrutinib vs bendamustine plus rituximab in patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without 17p deletions.

Paolo ghiaStrategic research programDivision of experimental oncologySan raffaele scientific instituteMedical oncologyB cell neoplasia unitVita salute san raffaeleExperimental oncologyAsh annual meeting and expositionOnclive tvChronić lymphocytic leukemia

vimarsana © 2020. All Rights Reserved.